Date: 19-Oct-2026
Intelligence Overview
The U.S. Food and Drug Administration (USFDA) has revised its Small Entity Compliance Guide: Safety Reporting Requirements for INDs and BA/BE Studies in October 2026. The guidance is intended to help small businesses, sponsors, and investigators understand the safety reporting requirements applicable to human drug and biological products investigated under an Investigational New Drug (IND) application or in bioavailability (BA) and bioequivalence (BE) studies exempt from IND requirements.
The latest revision updates the guidance history, replaces references to previously withdrawn guidance documents, and incorporates minor editorial changes to align the document with the FDA’s current regulatory guidance framework.
Key Regulatory Highlights
1. Applicability to Small Entities
Small entities must comply with applicable safety reporting regulations for IND studies under 21 CFR 312.32 and 312.64(b), as well as BA/BE studies under 21 CFR 320.31(d)(3). The guidance clarifies that these regulatory obligations also apply to sponsor-investigators conducting investigator-initiated studies.
2. Evaluation of Available Safety Information
Sponsors and sponsor-investigators must evaluate the safety information available to them to determine whether it meets the criteria for reporting. The FDA recommends actively seeking additional safety information through scientific literature reviews and sharing relevant safety information between entities involved in supplying or receiving investigational drugs.
3. Aggregate Safety Analysis
Sponsors should establish predefined safety monitoring plans that outline procedures for reviewing, evaluating, and managing safety information. Aggregate analyses of specific adverse events should be conducted across individual studies and, where applicable, across studies and INDs to determine whether expedited reporting criteria are met.
4. IND Annual Reports and IRB Reporting
The guidance clarifies that the revised safety reporting requirements did not change the existing requirements for IND annual reports under 21 CFR 312.33 or investigators’ reporting obligations to Institutional Review Boards (IRBs).
5. Updated Guidance References
The October 2026 revision reflects the FDA’s December 2025 guidance updates on sponsor responsibilities for safety reporting and safety assessment in IND and BA/BE studies, as well as investigator responsibilities for safety reporting involving investigational drugs and devices.
Regulatory Significance
This revision reinforces the importance of maintaining effective safety surveillance, documented safety assessment procedures, and appropriate reporting practices throughout clinical development and BA/BE studies. Sponsors and investigators should ensure that their internal procedures remain aligned with applicable FDA regulations and consult the latest relevant FDA guidance when evaluating reporting obligations.
For regulatory affairs, clinical operations, pharmacovigilance, and regulatory intelligence professionals, monitoring these updates can support timely review of internal procedures and help maintain awareness of evolving regulatory expectations.
Source: https://www.fda.gov/media/85124/download https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-and-babe-studies
